ADAC Medical Systems, thenewly created equipment division of ADAC Laboratories, will displayVantage, its simultaneous transmission-emission attenuation correctiontechnique for the Vertex adjustable dual-head gamma camera (SCAN6/1/94). The technique is
ADAC Medical Systems, thenewly created equipment division of ADAC Laboratories, will displayVantage, its simultaneous transmission-emission attenuation correctiontechnique for the Vertex adjustable dual-head gamma camera (SCAN6/1/94). The technique is useful in eliminating artifacts createdduring nuclear cardiology procedures. ADAC has submitted a 510(k)application with the Food and Drug Administration for the techniqueand expects to have marketing clearance by December.
ADAC, of Milpitas, CA, will emphasize the throughput advantagesof using Vantage with the gamma camera detectors in the 90ºconfiguration. This offers higher throughput compared to similartechniques used on triple-head cameras, according to Ian Farmer,vice president of nuclear medicine marketing. Picker, the onlyvendor with a simultaneous attenuation correction technique onthe market, uses the technology on its triple-head Prism 3000camera (SCAN 6/1/94).
ADAC will also display 511-KeV collimators for fluorodeoxyglucose(FDG) imaging with Vertex. ADAC expects the technique to showutility in oncology imaging, Farmer said.
On the radiology information systems side, ADAC HealthcareInformation Systems will highlight its QuadRIS product, introducedearlier this year. ADAC will also show its progress in developingan information system for mammography facilities.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.